Citadel Advisors »

Hoth Therapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Hoth Therapeutics (HOTH) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Hoth Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Hoth Therapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Hoth Therapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $232k 144k 1.62
2023-06-30 $61k 20k 3.00

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Tesla Motors Call Option (TSLA)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Spdr Gold Tr Gold Shs Call Option (GLD)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
Strategy Cl A New Call Option (MSTR)
Alphabet Cap Stk Cl A Call Option (GOOGL)
UnitedHealth Call Option (UNH)
Palantir Technologies Cl A Call Option (PLTR)
Netflix Call Option (NFLX)

View all positions for Citadel Advisors

Top funds holding Hoth Therapeutics

DRW Holdings
Vanguard Group
Geode Capital Management
Citadel Advisors
State Street Corporation
Susquehanna International
UBS Group
Northern Trust
Renaissance Technologies
Lido Advisors
Two Sigma Investments
Jane Street
Two Sigma Securities
Advisor Group Holdings
Tower Research Capital

View all funds holding Hoth Therapeutics